肿瘤免疫治疗及其药物研发进展
DOI:
作者:
作者单位:

中国药科大学药学院药剂系

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然基金面上资助项目 (No.81872823);中国药科大学“双一流”资助项目(No.CPU2018PZQ13)


Advances in tumor immunotherapy and drug research and development
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    分子生物学和肿瘤生物学的进步极大地改变了癌症治疗模式,大量的科学研究揭示了肿瘤免疫逃逸的机制,各种新型的肿瘤免疫治疗应运而生,成为继手术、放疗、化疗、靶向治疗后癌症的另一有效治疗手段。本文介绍了肿瘤细胞免疫逃逸的机制,并重点介绍了细胞因子免疫疗法、治疗性单克隆抗体免疫疗法、PD-1/PD-L1疗法、CAR-T疗法、肿瘤疫苗、溶瘤病毒等新型免疫疗法的设计原理、上市的生物药物及最新研究进展,同时对比了各免疫疗法的优缺点,为肿瘤免疫治疗中的药物研发提供思路。

    Abstract:

    The progress of molecular biology and tumor biology has greatly changed the mode of cancer treatment. A large number of scientific studies have revealed the mechanism of tumor immune evasion, and a variety of new types of tumor immunotherapy have emerged as the times require, which has become another effective treatment of cancer after surgery, radiotherapy, chemotherapy and targeted therapy. This paper introduces the mechanism of tumor cell immune escape, and focuses on the design principle, biological drugs and the latest research progress of new immunotherapy, such as cytokine immunotherapy, therapeutic monoclonal antibody immunotherapy, PD-1/PD-L1 therapy, CAR-T therapy, tumor vaccine, oncolytic virus and so on. At the same time, the advantages and disadvantages of various immunotherapies are compared to provide ideas for drug research and development in tumor immunotherapy.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-06-25
  • 最后修改日期:2020-07-10
  • 录用日期:2020-07-29
  • 在线发布日期:
  • 出版日期:

友情链接